SequelSEC

Aldeyra Therapeutics, Inc. ALDX

Pharmaceutical Preparations · CIK 0001341235 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2026-06-30
Operating income
-$5.85M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Aldeyra Therapeutics, Inc. (ALDX) reported net income of -$5.45M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Aldeyra Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Aldeyra Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$5.85M-$3.55M-$6.67M-$8.00M-$10.17M-$10.43M-$16.58M-$16.14M-$18.01M-$9.39M
Net income-$5.45M-$3.45M-$6.46M-$7.69M-$9.77M-$9.93M-$15.81M-$15.11M-$16.85M-$8.08M
Research & development$3.48M$2.41M$4.30M$5.43M$8.51M$7.42M$14.63M$12.44M$14.97M$6.18M
Weighted-average diluted sharesshares 60.32Mshares 60.32MUnavailableshares 60.13Mshares 60.05Mshares 59.89MUnavailableshares 59.53Mshares 59.41Mshares 59.41M
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-0.09$-0.06$-0.10$-0.13$-0.16$-0.17$-0.27$-0.25$-0.28$-0.14
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$2.37M$1.14M$2.36M$2.57M$1.66M$3.00M$1.95M$3.70M$3.04M$3.21M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Aldeyra Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalentsUnavailableUnavailable$70.04M$59.34M$41.24M$50.35M$54.53M$68.12M$71.03M$102.49M
Total assets$47.54M$66.48M$72.06M$77.80M$84.96M$93.20M$104.61M$117.32M$126.04M$141.30M
Current assets$47.38M$66.27M$71.78M$77.46M$84.56M$92.73M$104.07M$116.72M$125.65M$140.85M
Total liabilities$9.66M$24.33M$27.81M$28.56M$29.67M$29.60M$33.60M$32.22M$27.73M$27.88M
Current liabilities$9.66M$24.33M$27.81M$28.48M$29.53M$14.29M$18.60M$17.15M$27.59M$21.68M
Total equity incl. NCI$37.89M$42.16M$44.25M$49.24M$55.29M$63.60M$71.00M$85.10M$98.31M$113.42M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailable$0$0$0$0$15.10M$15.00M$15.00M$0$0
Accounts payable$137.48K$141.36K$158.46K$13.42K$1.46M$346.15K$180.45K$186.92K$254.43K$280.30K

Cash flow

Aldeyra Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$4.59M-$5.11M-$5.30M-$7.02M-$8.56M-$12.47M-$12.04M-$7.97M-$13.22M-$9.97M
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flow-$23.10K$0$16.00M$25.00M-$554.13K$7.29M-$1.56M$5.26M-$18.24M-$30.38M
Financing cash flow-$15.30M$71.14K$0$120.75K$0$1.00M$7.78K-$197.39K$0$18.19K
Net change in cash-$19.91M-$5.04M$10.70M$18.10M-$9.11M-$4.18M-$13.59M-$2.91M-$31.46M-$40.33M
Stock-based compensation$1.64M-$987.55K$1.09M$2.58M$196.56K$2.22M$1.26M$3.23M$1.94M$1.55M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Aldeyra Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio4.91x2.72x2.58x2.72x2.86x6.49x5.59x6.80x4.55x6.50x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailable0.00xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ALDX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-02-27View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.